鲍曼不动杆菌铁蛋白的抗氧化功能研究

【目的】克隆鲍曼不动杆菌铁蛋白(Abferritin)基因,并研究其抗氧化功能。【方法】荧光定量PCR检测氧化应激下Abferritin基因的表达量,并将其基因克隆到表达载体p ET28a以构建重组质粒p ET28a-Abferritin,转化大肠杆菌BL21(DE3)得到重组菌BL/p ET28aAbferritin,IPTG诱导目的蛋白表达并利用镍柱亲和层析纯化该蛋白。比色法测定Abferritin蛋白的Fe2+氧化酶活性,自由基清除实验测定其抗氧化功能。菌落计数法观察重组大肠杆菌在H2O2应激条件下的存活率。【结果】Abferritin基因在氧化应激下表达增高。重组质粒在大肠杆菌BL21(DE3)中高效表达,通过Ni2+亲和层析纯化获得了Abferritin蛋白。该蛋白具有Fe2+氧化酶活性,能有效减少氧自由基的形成及提高大肠杆菌抵抗氧化应激的能力。【结论】氧化应激能诱导Abferritin基因表达上调,且该蛋白具有亚铁氧化酶活性和抗氧化功能。     

人源DCF1基因原核表达载体构建及蛋白分离纯化

为了深入研究DCF1(Dendritic Cell Factor 1)基因的作用,以质粒pc DNA3.1-DCF1-TAT为模板体外扩增得到片段DCF1-TAT,将测序正确的目的片段克隆入原核表达载体p ET32a,转化大肠杆菌Rosetta(DE3),异丙基-β-D-硫代半乳糖苷(IPTG)诱导表达,并优化表达条件。以尿素溶解包涵体蛋白,并优化溶解条件,通过Ni离子亲和层析柱进行纯化,再透析复性目的蛋白。用SDS-PAGE检测目的蛋白的表达和纯化结果,并用Western blot进行验证。结果表明,重组表达载体p ET32a-DCF1-TAT构建成功,并在大肠杆菌Rosetta中成功表达。融合蛋白主要以包涵体形式存在,经过尿素溶解,Ni离子亲和层析柱纯化获得高纯度的目的蛋白。SDS-PAGE和Western blot检测结果显示蛋白分子量大小与预期结果相符。     

肺炎支原体铁吸收调节蛋白基因的克隆表达与纯化

[目的]克隆肺炎支原体铁吸收调节蛋白(Fur)基因并纯化Fur蛋白,为研究其生物学功能奠定基础。[方法]利用Clustal Omega分析肺炎支原体Fur蛋白及其同源序列并用MEGA6.0构建进化树,通过PCR扩增Fur基因并对其进行双酶切,然后连接到p ET28a,得到重组载体p ET28a-Fur,将其转化大肠杆菌BL21(DE3),利用IPTG诱导Fur蛋白表达,并通过亲和层析纯化Fur蛋白。[结果]多序列比对和进化树分析表明Mp含有一个Fur蛋白。克隆得到大小为477 bp的Fur基因,编码159个氨基酸。得到重组表达质粒p ET28a-Fur,该质粒能在大肠杆菌中能高效表达,并纯化得到重组Fur蛋白。[结论]成功克隆获得Mp Fur基因,在大肠杆菌中高效表达并获得高纯度Fur蛋白。     

重组人磷脂爬行酶1的原核表达及纯化

目的:建立重组人磷脂爬行酶1(hPLSCR1)原核表达及纯化工艺。方法:PCR扩增hPLSCR1编码基因并连接到原核表达载体pET-28a,转化大肠杆菌BL21(DE3)并进行诱导表达,Western印迹鉴定所表达蛋白;优化表达条件后,Ni2+柱亲和层析纯化重组蛋白。结果:构建了pET-28a-PLSCR1重组质粒,诱导表达后,经SDS-PAGE分析目的蛋白的表达量达32%,Ni2+金属螯合法纯化目的蛋白后纯度达到95%以上,Western印迹验证了融合蛋白的特异性。结论:建立了高效稳定的His-PLSCR1表达体系,获得大规模生产His-PLSCR1的分离纯化工艺,为进一步研究其蛋白功能奠定了基础。     

sTACI-Fc-Myc重组质粒的构建、原核表达及活性鉴定

目的:构建s TACI-Fc-Myc重组质粒,并进行原核表达和纯化具有生物活性的融合蛋白。方法:通过PCR法获得s TACI-Fc-Myc重组片段,然后把融合基因片段与原核载体p ET28a连接在一起,并构建p ET28a-s TACI-Fc-Myc重组子,并转入BL21(DE3)中进行表达,用蛋白A凝胶亲和层析柱进行纯化及酶联免疫吸附剂(ELISA)法测定其生物学活性。结果:获得了s TACI-Fc-Myc重组质粒,且该质粒可以在BL21(DE3)中表达,亲和层析柱纯化后纯度可达到95%以上,与BAFF的结合活性具有剂量依赖性,浓度达到5 ng/μL时,两者的吸附达到饱和。结论:成功构建了s TACI-Fc-Myc原核表达载体,并使有生物学活性的融合蛋白在BL21(DE3)上获得了稳定表达,为进一步研究并筛选高活性BAFF拮抗肽奠定了基础。     

幽门螺杆菌Dps蛋白的表达、纯化及活性测定

[目的]表达及纯化重组幽门螺杆菌(Helicobacter pylori) Dps(DNA protection during starvation)蛋白并测定其活性。[方法]依照Dps蛋白的基因序列,设计PCR引物,并以幽门螺杆菌基因组DNA为模板扩增Dps基因。将扩增产物回收后连接到p ET15b然后转化大肠杆菌,涂布在抗性平板,37℃过夜培养,然后使用PCR和测序验证阳性菌落。使用IPTG诱导重组Dps蛋白表达,并通过Ni~(2+)亲和层析纯化。测试Dps蛋白的亚铁氧化酶活性和抗氧化功能。[结果]通过PCR获得全长为438 bp的Dps基因,成功构建重组质粒p ET15b-Dps,它能编码分子量为18. 9 k Da的重组Dps蛋白。使用IPTG诱导目的蛋白表达,然后纯化得到Dps蛋白。Dps蛋白能够快速催化亚铁离子生成铁离子。与对照BSA蛋白相比,Dps蛋白具有较强的抑制氧自由基生成的活性。[结论]构建了重组质粒p ET15b-Dps,纯化获得Dps蛋白并测定了其亚铁氧化酶活性和抗氧化活性。     

抗EGFRvⅢ单链抗体的原核表达条件的优化及纯化

为了构建抗EGFRvⅢ单链抗体大肠杆菌表达体系,优化抗EGFRvⅢ单链抗体在大肠杆菌中的表达条件,并建立纯化方法。构建抗EGFRvⅢ单链抗体的pET-22b(+)重组质粒,将其转化到大肠杆菌BL21中,研究不同温度、不同浓度诱导剂对目的蛋白表达效率的影响。用Ni2+亲和层析纯化蛋白,并通过免疫印迹对其进行鉴定。抗EGFRvⅢ单链抗体重组质粒经NdeⅠ和XhoⅠ双酶切,菌落PCR和测序验证,结果显示重组质粒构建成功。SDS-PAGE结果表明BL21表达的目的蛋白相对分子量为29kD左右,与理论分子量一致,免疫印迹结果表明在29kD左右出现一条特异性条带,与SDS-PAGE结果一致。15℃和0.6μmol/L的诱导剂为抗EGFRvⅢ单链抗体的最佳诱导条件。本研究成功构建了抗EGFRvⅢ单链抗体大肠杆菌表达体系,并获得了大肠杆菌表达单链抗体的最佳诱导条件。     

铜绿假单胞菌LasR蛋白的表达及抗血清制备

目的将铜绿假单胞菌(Pseudomonas aeruginosa,PA)中的调控蛋白LasR在原核系统中进行表达,制备LasR抗血清,为PA中las调控系统的研究奠定基础。方法以PA模式菌株PAO1全基因组为模板,PCR扩增lasR基因,PCR产物用Bam HI/EcoRI双酶切连接至p GEX-4T-1载体,获得重组表达载体p GEX-4T-1-lasR;PCR产物经Nco I/Xho I双酶切连接至p ET28a载体,获得重组表达载体p ET28a-lasR。将重组表达载体分别转化至大肠杆菌感受态细胞BL21中,分别以异丙基-β-D-硫代半乳糖苷(isopropyl-β-D-thiogalactoside,IPTG)诱导表达GST-LasR和His-LasR蛋白,通过GST或Ni~(2+)亲和层析纯化重组蛋白。将纯化后的His-LasR蛋白免疫新西兰大白兔,制备LasR抗血清;纯化后的GST-LasR蛋白用于LasR抗血清ELISA效价的检测。结果 lasR基因序列大小为717 bp;成功构建p GEX-4T-1-lasR和p ET28a-lasR表达载体。构建的工程菌能够有效表达目的蛋白His-LasR和GST-LasR,蛋白纯度大于95%;LasR抗血清的效价为1∶60 000。结论在原核系统中成功表达了可溶性LasR重组蛋白,并获得高效价的LasR抗血清,为PA中las调控系统的研究奠定了基础。     

羊口疮病毒119蛋白表达、纯化和多克隆抗体的制备

[目的]克隆表达羊口疮病毒ORFV119蛋白,以纯化重组蛋白为免疫原制备鼠多克隆抗体,并鉴定抗体的特性。[方法]PCR扩增ORFV119基因,克隆入原核表达载体p ET-28a(+)中构建重组质粒p ET28a-119。经双酶切和测序正确后,转化感受态大肠杆菌BL21,IPTG诱导表达,SDS-PAGE鉴定融合蛋白表达情况。表达产物进行超声破碎和Ni柱纯化,之后目的蛋白免疫BALB/c小鼠,制备ORFV119多克隆抗体并对其通过中和实验进行鉴定。[结果]成功构建重组质粒p ET28a-119,在大肠杆菌BL21中ORFV119融合蛋白以部分可溶形式表达。可溶性目的蛋白纯化后作为免疫原制备鼠多克隆抗体,抗体效价达1∶12 800,中和实验显示该多抗具有保护作用,可减轻宿主细胞在病毒感染时的病变效应(中和效价66 ND50/m L)。[结论]成功诱导表达、纯化ORFV119蛋白并制备其多克隆抗体,为深入研究ORFV感染、发病机理及羊口疮疾病的临床诊断奠定基础。     

重组斑马鱼 p8蛋白的原核表达及纯化

目的：在大肠杆菌中重组表达斑马鱼p8蛋白并纯化。方法：PCR扩增斑马鱼p8蛋白基因编码区,连接到带有6×His标签的原核表达载体pET-28a中,构建重组表达质粒pET-28a-p8并转化大肠杆菌BL21（DE3）,用IPTG诱导表达;优化表达条件后用Ni^2＋柱纯化重组蛋白。结果：构建了pET-28a-p8重组质粒;目的蛋白在大肠杆菌中获得表达,亲和纯化后,SDS-PAGE显示相对分子质量为预期的12．8×10^3。结论：获得了斑马鱼p8融合蛋白,为其生物学功能研究奠定了基础。     

Tumor-specific gene expression patterns with gene expression profiles

Gene expression profiles of 14 common tumors and their counterpart normal tissues were analyzed with machine learning methods to address the problem of selection of tumor-specific genes and analysis of their differential expressions in tumor tissues. First, a variation of the Relief algorithm, “RFE_Relief algorithm” was proposed to learn the relations between genes and tissue types. Then, a support vector machine was employed to find the gene subset with the best classification performance for distinguishing cancerous tissues and their counterparts. After tissue-specific genes were removed, cross validation experiments were employed to demonstrate the common deregulated expressions of the selected gene in tumor tissues. The results indicate the existence of a specific expression fingerprint of these genes that is shared in different tumor tissues, and the hallmarks of the expression patterns of these genes in cancerous tissues are summarized at the end of this paper.     

Tumor-specific gene expression patterns with gene expression profiles

Gene expression profiles of 14 common tumors and their counterpart normal tissues were analyzed with machine learning methods to address the problem of selection of tumor-specific genes and analysis of their differential expressions in tumor tissues. First, a variation of the Relief algorithm, "RFE_Relief algorithm" was proposed to learn the relations between genes and tissue types. Then, a support vector machine was employed to find the gene subset with the best classification performance for distinguishing cancerous tissues and their counterparts. After tissue-specific genes were removed, cross validation experiments were employed to demonstrate the common deregulated expressions of the selected gene in tumor tissues. The results indicate the existence of a specific expression fingerprint of these genes that is shared in different tumor tissues, and the hallmarks of the expression patterns of these genes in cancerous tissues are summarized at the end of this paper.     

High-level expression of full-length antibodies using trans-complementing expression vectors

Recombinant antibodies are increasingly used as therapeutics for a wide variety of diseases. Generation of cell lines expressing high levels of recombinant antibody typically requires labor-intensive cloning and screening steps. We describe a mammalian expression system for the high-level production of full-length antibody molecules. It has been shown that the dihydrofolate reductase (DHFR) selectable marker can be divided into two fragments that, with the aid of a leucine zipper, can re-associate to form an active molecule. Using bicistronic vectors, we linked the expression of each antibody chain to the expression of a DHFR fragment. Survival in selective media requires expression of both DHFR fragments that, by virtue of these vectors, also selects for the expression of both antibody chains. Initial pools produced 5 microg of Ab/10(6) cells/d (qP = microg/10(6) cells/d). Expression of each antibody chain in conjunction with a portion of DHFR also leads to concurrent amplification of both antibody chains in the presence of methotrexate, a DHFR inhibitor, and results in a two- to fivefold increase in antibody production with basal qPs ranging from 10-25 ug/10(6) cells/d. Shake-flask cultures of amplified pools produced up to 600 mg/L of antibody in 7 days. This system allows for rapid generation of antibodies without cloning and greatly simplifies selection of cell lines for the production of potential antibody therapeutics.     

Mining gene expression profiles: expression signatures as cancer phenotypes

Many examples highlight the power of gene expression profiles, or signatures, to inform an understanding of biological phenotypes. This is perhaps best seen in the context of cancer, where expression signatures have tremendous power to identify new subtypes and to predict clinical outcomes. Although the ability to interpret the meaning of the individual genes in these signatures remains a challenge, this does not diminish the power of the signature to characterize biological states. The use of these signatures as surrogate phenotypes has been particularly important, linking diverse experimental systems that dissect the complexity of biological systems with the in vivo setting in a way that was not previously feasible.